Petra Acquisition, Inc. (NASDAQ:PAIC), in a press release today regarding it’s Phase 2b trials for REVTx-99, also announced that its shareholders approved its combination with biotech firm Revelation Biosciences in a meeting held last week.
Unfortunately, nothing has been filed yet and Petra did not disclose much information regarding the deal, including redemption figures. However, the combined company is expected to begin trading today on the Nasdaq under “REVB” and “REVBW”.
The SPAC recently added forward purchase agreements and a convertible note that added up to $12 million to its combination with Revelation. Of this amount, $4.5 million is to be used to backstop potential redemptions with financing from AXA Prime Impact Master Fund, LifeSci Venture Partners as well as other Petra and Revelation institutional investors. Meteora Capital and affiliates have also agreed to purchase 750,000 shares from redeeming shareholders and have agreed not to redeem themselves.
Petra initially announced its $128 million combination with Revelation on August 30. San Diego-based Revelation is developing two drug candidates aimed at treating respiratory diseases as well as a diagnostic device for diagnosing viral infections.
On December 1, it initiated Phase 2b trials for REVTx-99 to test its efficacy in treating the flu while this drug began Phase 1b trials for treating allergic rhinitis and chronic nasal congestion the month before.
ADVISORS
- Roth Capital Partners is acting as financial advisor to Revelation
- LifeSci Capital is acting as financial and capital markets advisor to Petra
- Loeb & Loeb LLP is acting as legal counsel to Petra
- Fox Rothschild LLP and J.P. Galda & Co are acting as legal counsel to Revelation
At the SPAC of Dawn Following Wednesday’s positive CPI readings, the market is set to ingest both new jobless claims and Core PPI inflation numbers at 8:30 am ET. It might take a particularly rosy result to offset the many factors of market volatility recent. One new one got added to the bingo card this...
One of the eternal questions surrounding SPACs has been their ability or inability to match the opportunity and the performance of the traditional IPO route, and it has become received wisdom on Wall Street that SPACs don’t match up. This is ostensibly born out in in the aggregate statistics that are frequently cited. But, downside...
At the SPAC of Dawn Despite the specter of recession looming, many of the hot technology sectors that SPACs favored during the boom times appear to be coming back on the menu. Ares II (NYSE:AACT) is reportedly angling to lock down a deal with an autonomous trucking firm. Northern Genesis II and Reinvent Y each...
Cantor Equity Partners II (NASDAQ:CEPT) filed another warrantless SPAC showing that the firm will not be slowing down despite Cantor CEO Howard Lutnick moving his attentions to the administration. The new $200 million SPAC would join Cantor Equity Partners I (NASDAQ:CEPO), which became the first SPAC to IPO this year and Cantor Equity Partners (NASDAQ:CEP),...
At the SPAC of Dawn US market futures continue to be flash dark red after a major down day saw SPAC-favorite exchange Nasdaq lose about -4% of its value leaving it running down -9.5% on the year. The sudden downturn has been somewhat personal for the administration as Trump Media (NASDAQ:DJT) itself fell about -11.5%...